Global Pulmonary Drugs Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Pulmonary Drugs Market Research Report 2024
The pulmonary drugs are used for treating the conditions affecting lungs. The pulmonary drugs are used from treating minor illnesses such as the common cold to cure long-term disorders such asthma. These agents are available in different forms such as oral tablets, oral liquids, and injections or inhalations. Inhalations deliver the medicine directly to the lungs, which can act directly on the lung tissues, minimizing systemic side effects.
According to Mr Accuracy reports new survey, global Pulmonary Drugs market is projected to reach US$ 70880 million in 2029, increasing from US$ 41400 million in 2022, with the CAGR of 7.9% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Pulmonary Drugs market research.
Increasing tobacco smoking is expected to augment global pulmonary drugs market growth over forecast period.
Increasing incidence of Chronic Obstructive Pulmonary Disease (COPD) is directly proportional to the tobacco smoking and exposure. According to the World Health Organization (WHO) 2021, tobacco smoking is the primary cause of COPD leading to around 90% of Chronic Obstructive Pulmonary Disease (COPD) cases. The irreversible damages caused due to smoke leads to adoption of lifestyle adjustments and medical treatments that includes years. Smokers are highly susceptible to respiratory diseases such as COPD and asthma. For instance, in March 2022, according Centers for Disease Control (CDC), 30.8 billion adults in the U.S. smoked. Nearly 40 billion U.S. adults still smoke cigarettes, and an estimated 2.55 billion middle and high school students use at least one tobacco product, including e-cigarettes according statistical data provided in March 2022. For instance, September 2020, according to artoicle published in National Center for Biotechnology Information, every day, about 1,600 U.S. youth younger than 18 years smoke their first cigarette. Each year, nearly half a billion U.S. citizens die prematurely of smoking or exposure to secondhand smoke. Another 16 billion live with a serious illness caused by smoking. Each year, the U.S. spends more than $225 billion on medical care to treat smoking-related disease in adults.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Pulmonary Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Sanofi SA
Meda Pharmaceuticals
Circassia Pharmaceuticals Plc.
AstraZeneca Plc.
GlaxoSmithKline Plc.
Mallinckrodt Pharmaceuticals Plc.
Cheisi Farmaceutici S.p.A
Zambon Company S.p.A
Alaxia SAS
Merck Sharp & Dohme Limited
Boehringer Ingelheim
Grifols, S.A.
Abbott Laboratories
AbbVie Inc.
Aerogen Pharma Ltd.
Aurobindo Pharma Ltd.
Celon Pharma SA
Cipla Ltd.
F. Hoffmann La Roche Ltd.
Glenmark Pharmaceuticals Ltd.
Lupin Ltd.
Medisol Lifescience Pvt. Ltd.
Novartis AG
Sumitomo Pharma Co. Ltd.
Teva Pharmaceutical Industries Ltd.
Vertex Pharmaceuticals Inc.
Wellona Pharma
Segment by Type
Inhaled Corticosteroids
Long Acting Beta-2 Agonists
Antihistamines
Vasodilators
Others
Asthma & COPD
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Pulmonary Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Pulmonary Drugs market is projected to reach US$ 70880 million in 2029, increasing from US$ 41400 million in 2022, with the CAGR of 7.9% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Pulmonary Drugs market research.
Increasing tobacco smoking is expected to augment global pulmonary drugs market growth over forecast period.
Increasing incidence of Chronic Obstructive Pulmonary Disease (COPD) is directly proportional to the tobacco smoking and exposure. According to the World Health Organization (WHO) 2021, tobacco smoking is the primary cause of COPD leading to around 90% of Chronic Obstructive Pulmonary Disease (COPD) cases. The irreversible damages caused due to smoke leads to adoption of lifestyle adjustments and medical treatments that includes years. Smokers are highly susceptible to respiratory diseases such as COPD and asthma. For instance, in March 2022, according Centers for Disease Control (CDC), 30.8 billion adults in the U.S. smoked. Nearly 40 billion U.S. adults still smoke cigarettes, and an estimated 2.55 billion middle and high school students use at least one tobacco product, including e-cigarettes according statistical data provided in March 2022. For instance, September 2020, according to artoicle published in National Center for Biotechnology Information, every day, about 1,600 U.S. youth younger than 18 years smoke their first cigarette. Each year, nearly half a billion U.S. citizens die prematurely of smoking or exposure to secondhand smoke. Another 16 billion live with a serious illness caused by smoking. Each year, the U.S. spends more than $225 billion on medical care to treat smoking-related disease in adults.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Pulmonary Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Sanofi SA
Meda Pharmaceuticals
Circassia Pharmaceuticals Plc.
AstraZeneca Plc.
GlaxoSmithKline Plc.
Mallinckrodt Pharmaceuticals Plc.
Cheisi Farmaceutici S.p.A
Zambon Company S.p.A
Alaxia SAS
Merck Sharp & Dohme Limited
Boehringer Ingelheim
Grifols, S.A.
Abbott Laboratories
AbbVie Inc.
Aerogen Pharma Ltd.
Aurobindo Pharma Ltd.
Celon Pharma SA
Cipla Ltd.
F. Hoffmann La Roche Ltd.
Glenmark Pharmaceuticals Ltd.
Lupin Ltd.
Medisol Lifescience Pvt. Ltd.
Novartis AG
Sumitomo Pharma Co. Ltd.
Teva Pharmaceutical Industries Ltd.
Vertex Pharmaceuticals Inc.
Wellona Pharma
Segment by Type
Inhaled Corticosteroids
Long Acting Beta-2 Agonists
Antihistamines
Vasodilators
Others
Segment by Application
Asthma & COPD
Allergic Rhinitis
Pulmonary Arterial Hypertension
Cystic Fibrosis
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Pulmonary Drugs report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices